Quick Takeaways
- Joseph S. Freedman filed SCHEDULE 13D/A for Eupraxia Pharmaceuticals Inc. Common Shares, no par value (EPRX).
- Disclosed ownership: 9%.
- Date of event: 13 Mar 2026.
Joseph S. Freedman - 13 Mar 2026 SCHEDULE 13D/A Report for Eupraxia Pharmaceuticals Inc. Common Shares, no par value (EPRX)
- Filing Manager
- Joseph S. Freedman
- Reporting Manager
- Joseph S. Freedman
- Symbol
- EPRX
- Shares outstanding
- 64,924,611 shares
- Disclosed Ownership
- 5,843,215 shares
- Ownership
- 9%
- Form type
- SCHEDULE 13D/A
- Filing time
- 16 Mar 2026, 21:56:43 UTC
- Date of event
- 13 Mar 2026
- Previous filing
- 26 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Joseph S. Freedman disclosed 9% ownership in Eupraxia Pharmaceuticals Inc. Common Shares, no par value (EPRX) on 13 Mar 2026."
What Changed
- Previous schedule filing date: 26 Sep 2025.
- Current filing was accepted on 16 Mar 2026, 21:56.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Joseph S. Freedman | 9% | 5,843,215 | 4,309,205 | 1,534,010 | /s/ Joseph S. Freedman | Joseph S. Freedman | 0002043590 |